Monopar Therapeutics Inc. announced that Dr. Andrew P. Mazar, the Company's Co-Founder, Executive Vice President of Research and Development, Chief Scientific Officer and Board Member, will be resigning from his position with the Company and as a member of the Company's Board of Directors effective April 8, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.811 USD | -12.77% | +32.71% | +138.39% |
05-24 | Monopar Therapeutics Names Karthik Radhakrishnan as CFO | MT |
05-24 | Monopar Therapeutics Inc. Announces CFO Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+138.39% | 16.26M | |
+51.85% | 59.28B | |
+41.42% | 40.94B | |
-5.25% | 40.17B | |
-5.16% | 28.69B | |
+12.79% | 26.63B | |
-20.18% | 18.89B | |
+30.88% | 12.46B | |
+0.61% | 12.42B | |
+25.06% | 12.26B |
- Stock Market
- Equities
- MNPR Stock
- News Monopar Therapeutics Inc.
- Monopar Therapeutics Announces Resignation of Andrew P. Mazar as Member of the Board of Directors, Effective April 8, 2022